SPRO Spero Therapeutics Inc.

+0.02  (+0%)
Previous Close 11.83
Open 11.92
Price To Book 1.84
Market Cap 207657445
Shares 17,523,835
Volume 42,777
Short Ratio
Av. Daily Volume 80,818

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data released May 23, 2018 - supportive of further development.
Healthy Volunteers (safety trial)
Phase 3 PK and DSMB data read 2H 2019.
Complicated urinary tract infections (cUTI)
Phase 1 data due 2H 2019.
Healthy Volunteers
Phase 1 top-line data due 2H 2019.
Healthy Volunteers

Latest News

  1. Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
  2. Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
  3. Expedia Shares Fall as Home-Rental Business Vrbo Goes Slow
  4. Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for
  5. Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  6. Marriott Is Officially Getting Into the Homesharing Business
  7. Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
  8. Spero Gets Fast Track Designation for SPR994, Shares Improve
  9. Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
  10. Spero Announces Appointment of Cynthia Smith to its Board of Directors
  11. Will Spero Therapeutics Continue to Surge Higher?
  12. Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
  13. Airbnb, HomeAway lose legal challenge to Santa Monica rules
  14. Airbnb Loses Major Fight Over California City's Rental Law
  15. Spero Therapeutics to Present at March Investor Conferences
  16. Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
  17. Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?
  18. The travel industry is extremely resilient, says Expedia CEO
  19. Expedia Analysts Grow More Bullish After Strong Earnings